May 2019- Volume 15, Issue 5

In this Issue

Commentary

Out of Order: Of mice and…well…other mice

Out of Order: Of mice and…well…other mice

Trying to present the news without too much fanfare (and with maximum accuracy) means resisting temptation, but it's effort well-spent

Guest Commentary: Moving beyond regulatory analytical requirements for better biotherapeutics

Guest Commentary: Moving beyond regulatory analytical requirements for better biotherapeutics

There are several analytical methods that must be developed for biotherapeutics; among the most important of these are host cell proteins

Business & Government Policy

Patent Docs: A Solution in Search of a Problem

Patent Docs: A Solution in Search of a Problem

Kevin Noonan discusses the Biologic Patent Transparency Act and how he thinks the U.S. Congress might be picking the wrong target (patents) as a way to decrease drug prices and increase transparency

Wings Therapeutics launches

Wings Therapeutics launches

ProQR spins out all dystrophic epidermolysis bullosa activities

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Eisai buys out Purdue rights

Eisai buys out Purdue rights

Move officially ends collaboration on sleep-wake regulation agent

A hefty price tag for NLRP3

A hefty price tag for NLRP3

Novartis snaps up subsidiary IFM Tre and trio of NLRP3 antagonist molecules

Clinical Trials

Improving the experimental landscape

Improving the experimental landscape

CRA and TLS’ VISITOR take different paths toward road to clinical trials, success of new drugs

Bile acid modulation

Bile acid modulation

Drug aids in reducing rare pediatric liver disease

Plenty of momentum for inarigivir

Plenty of momentum for inarigivir

Spring Bank reports positive response from ACHIEVE trial, kicks off CATALYST trials

Guselkumab goes into development for FAP

Guselkumab goes into development for FAP

MorphoSys announces that licensee Janssen has expanded clinical development of drug into familial adenomatous polyposis

Preclinical

Triggering clean-up lessens inflammation

Triggering clean-up lessens inflammation

Inhibiting choline kinase leads to mitophagy, which could stave off inflammasome activation

Notable results for NYX-458

Notable results for NYX-458

Data in Parkinson’s disease model demonstrate reversal of cognitive deficits with NYX-458

Advancing apace with ADAPTIR

Advancing apace with ADAPTIR

Aptevo advances bispecific candidates, sees encouraging preclinical data

A gene therapy for wet AMD

A gene therapy for wet AMD

Adverum presents first preclinical data on dosing contralateral eye with ADVM-022

Q&A

Q&A: Concern as NAFLD and NASH rates rise

Q&A: Concern as NAFLD and NASH rates rise

DDNews speaks with Mount Sinai researcher about the past, present and future of these liver conditions

Research & Development

Through the ages

Through the ages

Two unique research paths emerge, looking at the fundamentals of aging and ancient origins of disease

Splice-Break finds key DNA deletions

Splice-Break finds key DNA deletions

A new approach to studying deletions in the mitochondria could inform disease study

A booster for immuno-oncology drugs

A booster for immuno-oncology drugs

Australia’s Noxopharm unveils preclinical results on idronoxil

Disruptive double agent

Disruptive double agent

Existing drug may successfully treat aggressive tumor

Contract Services

Modeling proteins better

Modeling proteins better

Sygnature Discovery announces collaboration with software firm SilcsBio

A platform partnership

A platform partnership

CrownBio and HUB ink license agreement to offer their PDX and organoid platforms together

Vetter’s Skokie facility expansion nears completion

Vetter’s Skokie facility expansion nears completion

Facility growth is necessary to help meet customer demands and new product requirements

Discovery

Machine learning vs. NASH

Machine learning vs. NASH

Gilead Sciences and insitro launch collaboration for AI-enabled drug discovery against NASH

Keep a good thing going

Keep a good thing going

Expanded collaboration in Huntington’s disease research to explore stem cell and genetic therapeutics

Managing the microbiome

Managing the microbiome

A roundup of a few recent news stories related to microbiome discoveries

A fifth collaboration for AI-driven firm

A fifth collaboration for AI-driven firm

Ono and twoXAR announce neurological drug discovery deal

Interest in inosine

Interest in inosine

ALS cells lose critical enzyme that protects neuronal cells

Diagnostics

Real-world data vs. MS

Real-world data vs. MS

Clinico-genomic collaboration propels multiple sclerosis research

Predicting obesity?

Predicting obesity?

Researchers may be able to use genetic profiles to predict obesity risk at birth

Getting more eyes on glaucoma

Getting more eyes on glaucoma

Mannin Research, Biointerfaces Institute to pursue GDF15 biomarker diagnostic for eye disease

Homing in on PTSD

Homing in on PTSD

IU researchers discover potential test for post-traumatic stress disorder

Editor's Focus

Editor's focus: Vaccines increasingly under perilous scrutiny

Editor's focus: Vaccines increasingly under perilous scrutiny

Vaccines hardly deserve the suspicion they're being faced with of late, but developers need to keep their standards high and meet it nonetheless

Feature

At the forefront of cancer research

At the forefront of cancer research

We look at FLIP, STING and other potentially groundbreaking areas of oncology therapeutics R&D

ISSCR Show Preview: Sunny days for stem cells

ISSCR Show Preview: Sunny days for stem cells

ISSCR makes its way to sunny L.A. for its 17th annual meeting
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue